Journal of Breast Cancer

Korean Breast Cancer Society (한국유방암학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Significance of Age at the Time of Diagnosis among Young Breast Cancer Patients

  • Kim, Im-Kyung (Department of Surgery, Yonsei University College of Medicine) ;
  • Park, Se-Ho (Department of Surgery, Yonsei University College of Medicine) ;
  • Hwang, Hye-Won (Department of Surgery, Yonsei University College of Medicine) ;
  • Lee, Jun-Sang (Department of Surgery, Yonsei University College of Medicine) ;
  • Ko, Si-Mon (Department of Surgery, Yonsei University College of Medicine) ;
  • Kim, Seung-Il (Department of Surgery, Yonsei University College of Medicine) ;
  • Park, Byeong-Woo (Department of Surgery, Yonsei University College of Medicine)
  • Published : 2011.12.31
⟨ Previous Next ⟩

Abstract

Purpose: The aims of this study were to investigate outcomes corresponding to age at diagnosis as categorized into 5-year intervals and to explore whether endocrine-responsive tumors display clinical benefits from endocrine therapy after chemotherapy among young breast cancer patients. Methods: A total of 1,171 patients who were under 40 years old at diagnosis between 1985 and 2007 were divided into 3 subgroups: ${\leq}30years$ (Group I, 13.3%), 31-35 years (Group II, 30.5%), and 36-40 years (Control group, 56.2%). Clinicopathological factors and outcomes were compared using a chi-square test, the Kaplan-Meier method, and Cox's hazards models. Results: There were no significant differences in the characteristics and treatment patterns between the 3 groups, except for the grade, hormone receptors expression, and use of endocrine therap. Group I showed the worst survival and subsequently Group II presented worse outcomes than the Control group, mainly among hormone receptors-positive patients. Groups I and II showed increased risks of recurrence and death in multivariate analyses. Among 529 hormone receptors-positive patients who received chemotherapy, favorable outcomes for patients who were treated with endocrine agents were demonstrated, mainly in patients aged 35 years or less. However, interaction tests between the use of endocrine therapy and age at diagnosis were not significant. Conclusion: Age at diagnosis is an independent prognostic factor and the age of 35 years is a rational cut-off among young patients. Our subgroup analysis suggests that endocrine therapy may provide additional benefits even in young breast cancers. Therefore, further researches should be directed towards improving outcomes for this population.

Keywords

References

  1. Elkum N, Dermime S, Ajarim D, Al-Zahrani A, Alsayed A, Tulbah A, et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer 2007;7:222. https://doi.org/10.1186/1471-2407-7-222
  2. Tarone RE. Breast cancer trends among young women in the United States. Epidemiology 2006;17:588-90. https://doi.org/10.1097/01.ede.0000229195.98786.ee
  3. Shin HR, Jung KW, Won YJ, Park JG; 139 KCCR-affiliated Hospitals. 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 2004;36:103-14. https://doi.org/10.4143/crt.2004.36.2.103
  4. Han W, Kim SW, Park IA, Kang D, Kim SW, Youn YK, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 2004;4:82. https://doi.org/10.1186/1471-2407-4-82
  5. Ko SS; Korean Breast Cancer Society. Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996-2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol 2008;98:318-23. https://doi.org/10.1002/jso.21110
  6. Han W, Kang SY; Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 2010;119:193-200. https://doi.org/10.1007/s10549-009-0388-z
  7. Kim EK, Noh WC, Han W, Noh DY. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg 2011;35:1244-53. https://doi.org/10.1007/s00268-011-1071-1
  8. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-83. https://doi.org/10.1093/annonc/mdi326
  9. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355:1869-74. https://doi.org/10.1016/S0140-6736(00)02292-3
  10. Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 2001;(30):44-51.
  11. Jung M, Shin HJ, Rha SY, Jeung HC, Hong S, Moon YW, et al. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. Ann Surg Oncol 2010;17:3259-68. https://doi.org/10.1245/s10434-010-1172-3
  12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717. https://doi.org/10.1016/S0140-6736(05)66544-0
  13. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. J Clin Oncol 2007;25:2360-8. https://doi.org/10.1200/JCO.2006.10.3754
  14. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
  15. Kang BM, Jung JH, Lim YS, Park HY, Lee YH. Clinical significance of age for premenopausal women with primary breast cancer. J Breast Cancer 2006;9:323-9. https://doi.org/10.4048/jbc.2006.9.4.323
  16. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer 2001;92:2523-8. https://doi.org/10.1002/1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6
  17. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 1994;(16):35-42.
  18. Park BW, Kim SI, Kim EK, Yang WI, Lee KS. Impact of patient age on the outcome of primary breast carcinoma. J Surg Oncol 2002;80:12-8. https://doi.org/10.1002/jso.10088
  19. Weber-Mangal S, Sinn HP, Popp S, Klaes R, Emig R, Bentz M, et al. Breast cancer in young women ( https://doi.org/10.1002/ijc.11460
  20. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000;320:474-8. https://doi.org/10.1136/bmj.320.7233.474
  21. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997;89:1673-82. https://doi.org/10.1093/jnci/89.22.1673
  22. Lee EH, Park SK, Park B, Kim SW, Lee MH, Ahn SH, et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat 2010;122:11-25. https://doi.org/10.1007/s10549-010-0859-2
  23. Son BH, Ahn SH, Lee MH, Park SK, Kim SW; Korean Breast Cancer Society. Hereditary breast cancer in Korea: a review of the literature. J Breast Cancer 2008;11:1-9. https://doi.org/10.4048/jbc.2008.11.1.1
  24. Han SA, Park SK, Ahn SH, Son BH, Lee MH, Choi DH, et al. The breast and ovarian cancer risks in Korea due to inherited mutations in BRCA1 and BRCA2: a preliminary report. J Breast Cancer 2009;12:92-9. https://doi.org/10.4048/jbc.2009.12.2.92
  25. Koo DH, Chung IY, Kang E, Han SA, Kim SW. Usage patterns of surveillance, chemoprevention and risk-reducing surgery in Korean BRCA mutation carriers: 5 years of experience at a single institution. J Breast Cancer 2011;14(Suppl 1):S17-23. https://doi.org/10.4048/jbc.2011.14.S.S17
  26. Narod SA. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010;7:702-7. https://doi.org/10.1038/nrclinonc.2010.166
  27. Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 2009;15:323-39. https://doi.org/10.1093/humupd/dmn064

Cited by

  1. Young Women with Breast Cancer in the United States and South Korea: Comparison of Demographics, Pathology and Management vol.16, pp.6, 2015, https://doi.org/10.7314/apjcp.2015.16.6.2531
  2. Comparison of Clinicopathological Features and Treatments between Young (≤40 Years) and Older (>40 Years) Female Breast Cancer Patients in West China: A Retrospective, Epidemiological, Multicenter vol.11, pp.3, 2016, https://doi.org/10.1371/journal.pone.0152312